Dean Tuck – Managing Director – Dreadnought Resources (ASX:DRE) is a highly active West Australian mineral explorer focused on finding the metals needed now and in the future.
Copyright 2024 – Finance News Network
Source: Finance News Network
11 Aug 2025 - Inside Etherstack’s multi-year partnership with the world’s largest telecom
Read More03 Dec 2019 - Synertec Corporation Limited (ASX:SOP) Managing Director, Michael Carroll & CFO, David Harris talk FY19 results, market conditions and the outlook for specialist engineering and compliance services.
Read More17 Aug 2022 - WT Financial Group Limited (ASX:WTL) Founder and Managing Director Keith Cullen discusses the company's indicative results and the future of financial advice.
Read More06 Sep 2023 - GBM Resources Limited (ASX:GBZ) Managing Director Peter Rohner provides an update on the company's projects, discussing the JV with Newcrest Mining (ASX:NCM) and recent divestments.
Read More12 Aug 2024 - Jindalee Lithium Limited (ASX:JLL) CEO Ian Rodger provides an overview of the company, discussing the McDermitt project, progress on the PFS and grant funding.
Read More16 March 2022 - WT Financial Group Limited (ASX:WTL) Founder and Managing Director Keith Cullen discusses the acquisition of Synchron and what this means for WT.
Read More16 Aug 2023 - Dr John Melki - CEO and Director - Genetic Signatures (ASX:GSS) is transforming molecular diagnostics via streamlined sample processing methods linked to highly multiplexed real-time PCR screening assays.
Read More28 Feb 2022 - BHP Group Limited (ASX:BHP) CEO Mike Henry and CFO David Lamont provide a shareholder update with Gabrielle Notley, Head of Corporate Communications.
Read More15 Oct 2024 - Nathan Simiana, Director for Industrials and Smart Manufacturing at Deloitte, discusses transforming industry through data-driven decision-making.
Read More30 Mar 2022 - Immutep Limited (ASX:IMM) Executive Director and CEO Marc Voigt discusses the company's LAG-3-related therapies, outlining future plans and expected data readouts for Immutep's lead drug, eftilagimod alpha.
Read More
